Bradley Saenger
Known title: Chief Financial OfficerCIK: 0001668150
Associated companies
Transaction History
| TNXP | ▼ Sell | Other | 1,453 | $16K | 6/30/2026 | View on chart |
| TNXP | ▼ Sell | Other | 0 | $0 | 2/5/2025 | View on chart |
| TNXP | ▼ Sell | Other | 1,453 | $16K | 6/30/2026 | View on chart |
| TNXP | ▼ Sell | Other | 0 | $0 | 2/5/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TNXP Secures Second Medicare Agreement for TONMYA
Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its drug TONMYA. The deal expands the drug’s coverage and could increase patient access. The agreement follows the first Medicare agreement and supports the company’s growth strategy. The news may influence investor perception of the drug’s commercial potential.
TNXP Secures Second Medicare Agreement for TONMYA. Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its drug TONMYA. The deal expands the drug’s coverage and could increase patient access. The agreement follows the first Medicare agreement and supports the company’s growth strategy. The news may influence investor perception of the drug’s commercial potential.